Bidil and Fainting - a phase IV clinical study of FDA data

Summary:

Fainting is reported as a side effect among people who take Bidil (hydralazine hydrochloride; isosorbide dinitrate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Coreg, and have Cardiac failure congestive.

The phase IV clinical study analyzes which people have Fainting when taking Bidil. It is created by eHealthMe based on reports of 511 people who have side effects when taking Bidil from the FDA, and is updated regularly.

What is Bidil?

Bidil has active ingredients of hydralazine hydrochloride; isosorbide dinitrate. eHealthMe is studying from 520 Bidil users. Check the latest studies of Bidil.

What is Fainting?

Fainting (loss of consciousness and postural tone) is found to be associated with 2,451 drugs and 3,548 conditions by eHealthMe. Check the latest studies of Fainting.

On Aug, 11, 2026

511 people reported to have side effects when taking Bidil.
Among them, 15 people (2.94%) have Fainting.

Among these 15 people:

How long have people been on Bidil when they have Fainting? *

What is the gender of people who have Fainting when taking Bidil? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Fainting when taking Bidil? *

What are other drugs people take besides Bidil? *

What are other side effects people have besides Fainting? *

Nausea (feeling of having an urge to vomit): 6 people, 40.00%
Dizziness: 5 people, 33.33%
Anaemia (lack of blood): 5 people, 33.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 33.33%
Hypotension (abnormally low blood pressure): 4 people, 26.67%
Fatigue (feeling of tiredness): 4 people, 26.67%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 4 people, 26.67%
Diarrhea: 4 people, 26.67%
Loss Of Consciousness: 4 people, 26.67%
Cardiac Failure Congestive: 4 people, 26.67%

What are the existing conditions these people have? *

Cardiac Failure Congestive: 4 people, 26.67%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 20.00%
High Blood Pressure: 3 people, 20.00%
Pain: 2 people, 13.33%
Neoplasm Malignant (cancer tumour): 2 people, 13.33%
Breast Cancer Metastatic: 2 people, 13.33%
Cardiac Failure: 2 people, 13.33%
Diabetes: 2 people, 13.33%
Cardiomyopathy (weakening of the heart muscle): 2 people, 13.33%
Type 2 Diabetes: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Bidil and have Fainting?

- Check whether Fainting is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bidil:

Bidil (520 reports)

Fainting treatments and more:

Fainting (131,321 reports)

How severe was Fainting and when was it recovered:

Fainting in Bidil

Expand to all the drugs that have ingredients of hydralazine hydrochloride; isosorbide dinitrate:

Fainting and drugs with ingredients of hydralazine hydrochloride; isosorbide dinitrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Bidil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fainting:

Fainting (2,451 drugs)

Browse all the conditions that are associated with Fainting:

Fainting (3,548 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydralazine hydrochloride; isosorbide dinitrate (the active ingredients of Bidil) and Bidil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.